Researchers Argue There is a Difference in Specificity Depending on what test is used for Lyme Disease


 

Background: Authors explain that their are different methods to diagnose of Lyme disease using different serologic approaches and immunoblot criteria. The authors compare the sensitivity and specificity of various methods, such as the CDC two-tiered approach, the modified two-tiered approach, and the single-tier alternative immunoblot assays.

Purpose: The authors aim to evaluate the performance of two alternative immunoblot criteria (labeled A and B) that use antigens from multiple Borrelia burgdorferi strains and require fewer positive bands than the CDC criteria. They use data from multiple FDA-cleared immunoblot test kits and compare the results to the CDC criteria and the modified two-tiered approach1.

Methods: The authors use eight different datasets from various sources, including the CDC Lyme Serum Repository, to assess the analytical performance and clinical accuracy of the immunoblot test kits. They use statistical analyses such as confidence intervals, McNemar’s test, Fisher’s exact test, likelihood ratios, and meta-analyses to compare the proportions, differences, and heterogeneity of the test results.
References: The page contains many references to previous studies and guidelines on Lyme disease serology, immunoblotting, and alternative criteria. The references are numbered and linked to the corresponding citations at the end of the page.

Conclusions:The authors conclude that:

The single-tier alternative immunoblot interpretive criteria, applied to both IgG and IgM immunoblots, demonstrated significantly more false-positive or equivocal results in healthy controls than two-tiered CDC criteria1.

The single-tier alternative immunoblot interpretive criteria also showed lower specificity in patients with potentially cross-reacting medical conditions than two-tiered CDC criteria.
The single-tier alternative immunoblot interpretive criteria did not demonstrate improved sensitivity for early Lyme disease compared to two-tiered CDC criteria or modified two-tiered all-EIA assays.


Porwancher R, Levin A, Trevejo R. Immunoblot Criteria for Diagnosis of Lyme Disease: A Comparison of CDC Criteria to Alternative Interpretive Approaches. Pathogens. 2023 Oct 26;12(11):1282. doi: 10.3390/pathogens12111282. PMID: 38003747; PMCID: PMC10674374.

Comments